Crucell, DSM Biologics Partner with Invitrogen

Crucell and DSM Biologics have chosen Invitrogen to enter its partnership for the PER.C6 licensing business Vendor Network for monoclonal antibodies and recombinant proteins.

Through its PD-Direct services, Invitrogen has experience with the PER.C6 technology and will offer PER.C6 licensees the benefit of expertise developed as a leader in clone generation services. Invitrogen will also continue to develop and optimize clone generation solutions specifically tailored to the PER.C6 human cell line.

The Vendor Network was created to develop and provide high-quality biotechnology tools and services tailored to PER.C6. It will consist of leading tool and service providers offering, for example, PER.C6 clone generation programs, medium, bioreactor and other production equipment and devices, and process development services. The vendors will enhance the performance of the PER.C6 technology platform.